{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:27:23Z","timestamp":1783110443257,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118705","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:31:21Z","timestamp":1778758281000},"page":"118705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer"],"prefix":"10.1016","volume":"139","author":[{"given":"Chin Leong","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Yuen Kwan","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Shing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118705_bb0005","unstructured":"National Cancer Institute. (2025). SEER cancer stat facts: Ovarian cancer. Retrieved October 24, 2025, from https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"10.1016\/j.bmc.2026.118705_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-025-08771-9","article-title":"Overcoming platinum-resistant ovarian cancer targeting the activated JAK-STAT pathways via extracellular vesicles","volume":"8","author":"Suzuki","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.bmc.2026.118705_bb0015","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/DDDT.S207720","article-title":"Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties","volume":"13","author":"Gallelli","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.bmc.2026.118705_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/phrs.2001.0847","article-title":"Aescin: pharmacology, pharmacokinetics and therapeutic profile","volume":"44","author":"Sirtori","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118705_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.02.027","article-title":"Molecular targets and anti-cancer potential of escin","volume":"422","author":"Cheong","year":"2018","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.bmc.2026.118705_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/biom13020315","article-title":"Escin's multifaceted therapeutic profile in treatment and post-treatment of various cancers: a comprehensive review","volume":"13","author":"Fazliev","year":"2023","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.bmc.2026.118705_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163931","article-title":"The natural product \u03b2-escin targets cancer and stromal cells of the tumor microenvironment to inhibit ovarian cancer metastasis","volume":"13","author":"Kenny","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118705_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s40495-015-0019-9","article-title":"Anti-inflammatory and anti-cancer properties of \u03b2-escin, a triterpene saponin","volume":"1","author":"Patlolla","year":"2015","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.bmc.2026.118705_bb0045","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/196952a0","article-title":"Action of saponin on biological cell membranes","volume":"196","author":"Bangham","year":"1962","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bmc.2026.118705_bb0050","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.bmc.2012.03.032","article-title":"Saponins can perturb biologic membranes and reduce the surface tension of aqueous solutions: a correlation?","volume":"20","author":"B\u00f6ttger","year":"2012","journal-title":"Bioorg Med Chem"},{"issue":"44","key":"10.1016\/j.bmc.2026.118705_bb0055","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1039\/C4OB01652A","article-title":"The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells","volume":"12","author":"Lorent","year":"2014","journal-title":"Org Biomol Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118705_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jep.2013.11.039","article-title":"Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats","volume":"151","author":"Wu","year":"2014","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118705_bb0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/ph16030386","article-title":"Saponins of selected triterpenoids as potential therapeutic agents: a review","volume":"16","author":"Bildziukevich","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.bmc.2026.118705_bb0070","first-page":"339","article-title":"Structure-activity relationships of oleanane- and ursane-type triterpenoids","volume":"47","author":"Sun","year":"2006","journal-title":"Bot Stud"},{"key":"10.1016\/j.bmc.2026.118705_bb0075","first-page":"2075","article-title":"Bardoxolone methyl (CDDO-me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties","volume":"8","author":"Wang","year":"2014","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.bmc.2026.118705_bb0080","first-page":"15","article-title":"A review of structural modification and biological activities of oleanolic acid","volume":"22","author":"Yang","year":"2024","journal-title":"Chin J Nat Med"},{"issue":"2","key":"10.1016\/j.bmc.2026.118705_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.15406\/ppij.2021.09.00329","article-title":"Creation of a novel triterpenoid drug that inhibits DNA synthesis","volume":"9","author":"Chan","year":"2021","journal-title":"Pharm Pharmacol Int J"},{"issue":"2","key":"10.1016\/j.bmc.2026.118705_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"de Bree","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.bmc.2026.118705_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10147-025-02700-w","article-title":"Intraperitoneal chemotherapy is now back for ovarian cancer","volume":"30","author":"Fujiwara","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bmc.2026.118705_bb0100","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118705_bb0105","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200225","article-title":"Intraperitoneal carboplatin for ovarian cancer\u2014a phase 2\/3 trial","volume":"2","author":"Nagao","year":"2023","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.bmc.2026.118705_bb0110","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e58","article-title":"Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands","volume":"31","author":"Burg","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118705_bb0115","article-title":"Diagnosis and management of peritoneal metastases from ovarian cancer","volume":"2012","author":"Halkia","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"10.1016\/j.bmc.2026.118705_bb0120","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.3390\/molecules18044389","article-title":"Preparation, purification and regioselective functionalization of protoescigenin\u2014the main aglycone of escin complex","volume":"18","author":"Gruza","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118705_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpba.2012.03.019","article-title":"Charged aerosol detection in pharmaceutical analysis","volume":"69","author":"Almeling","year":"2012","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"10.1016\/j.bmc.2026.118705_bb0130","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-025-02195-9","article-title":"A clinical pharmacological perspective on intraperitoneal chemotherapy","volume":"85","author":"Rietveld","year":"2025","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.bmc.2026.118705_bb0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tibtech.2011.06.010","article-title":"Bioluminescence imaging: Progress and applications","volume":"29","author":"Badr","year":"2011","journal-title":"Trends Biotechnol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118705_bb0140","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3892\/ijo.2017.4115","article-title":"Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: a comparative study","volume":"51","author":"Guo","year":"2017","journal-title":"Int J Oncol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:11:46Z","timestamp":1783109506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S0968089626001616"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118705","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118705"}}